Objectives: Transition from originator biological medicines to their biosimilar equivalents is now part of routine clinical practice, but there is little understanding of patient experiences, which influence adherence and overall satisfaction with care. Understanding this will help ensure future switches adequately address patients' concerns and expectations leading to better outcomes for all stakeholders. Method: 35 patients participating in a clinical trial including an open-label transition event from originator to biosimilar adalimumab, mimicking what would be encountered in a real-world setting, took part in semi-structured interviews exploring their experience of biosimilar transition. Results: Opinions expressed were often heterogene...
Funding Information: The authors acknowledge all patients for their participation. We also like to t...
Adalimumab is currently the only biological medicine approved by the FDA for the treatment of hidrad...
Background: A biosimilar is a biological medicine highly similar to another already approved biologi...
Objectives To investigate the perceptions and experiences of people with specific immune-mediated in...
Ira Jacobs,1 Ena Singh,2 K Lea Sewell,3 Ahmad AL-Sabbagh,1 Lesley G Shane1 1Global Established Phar...
No data are available regarding the safety and effectiveness of the biosimilar-to-biosimilar switch ...
Item does not contain fulltextOBJECTIVE: To survey patients' experiences with the switch from an ori...
Background and objectives: Biosimilar medicines have been on the European market for 15 years. Despi...
Despite several studies proving the efficacy and safety of biosimilars compared with original drugs,...
Few data are available on subjective disease control and perception of adverse events (AEs) during s...
John Waller,1 Emma Sullivan,1 James Piercy,1 Christopher M Black,2 Sumesh Kachroo2 1Adelphi Real Wo...
International audienceObjective : To study acceptance rate and factors influencing acceptance of the...
The licensing of biosimilars heralds the start of a new era for physicians treating immune and infla...
This study examined gastroenterologists' motivation for prescribing biosimilars, assessed their trea...
Background Infliximab and etanercept biosimilars present significant potential cost savings to the ...
Funding Information: The authors acknowledge all patients for their participation. We also like to t...
Adalimumab is currently the only biological medicine approved by the FDA for the treatment of hidrad...
Background: A biosimilar is a biological medicine highly similar to another already approved biologi...
Objectives To investigate the perceptions and experiences of people with specific immune-mediated in...
Ira Jacobs,1 Ena Singh,2 K Lea Sewell,3 Ahmad AL-Sabbagh,1 Lesley G Shane1 1Global Established Phar...
No data are available regarding the safety and effectiveness of the biosimilar-to-biosimilar switch ...
Item does not contain fulltextOBJECTIVE: To survey patients' experiences with the switch from an ori...
Background and objectives: Biosimilar medicines have been on the European market for 15 years. Despi...
Despite several studies proving the efficacy and safety of biosimilars compared with original drugs,...
Few data are available on subjective disease control and perception of adverse events (AEs) during s...
John Waller,1 Emma Sullivan,1 James Piercy,1 Christopher M Black,2 Sumesh Kachroo2 1Adelphi Real Wo...
International audienceObjective : To study acceptance rate and factors influencing acceptance of the...
The licensing of biosimilars heralds the start of a new era for physicians treating immune and infla...
This study examined gastroenterologists' motivation for prescribing biosimilars, assessed their trea...
Background Infliximab and etanercept biosimilars present significant potential cost savings to the ...
Funding Information: The authors acknowledge all patients for their participation. We also like to t...
Adalimumab is currently the only biological medicine approved by the FDA for the treatment of hidrad...
Background: A biosimilar is a biological medicine highly similar to another already approved biologi...